Sirolimus and hydroxychloroquine 400 mg (DrugBank: Sirolimus, Hydroxychloroquine)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 89 | Lymphangioleiomyomatosis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01687179 (ClinicalTrials.gov) | September 2012 | 2/8/2012 | Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis | Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus | Lymphangioleiomyomatosis | Drug: Sirolimus and Hydroxychloroquine 200 mg;Drug: Sirolimus and Hydroxychloroquine 400 mg | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | 85 Years | Female | 14 | Phase 1 | United States |